Wolverine Trading
PGNX

Wolverine Trading’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Wolverine Trading’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-21,600
Closed -$110K – 5664
2019
Q4 		$110K Sell
21,600
-200
-0.9% -$1.06K ﹤0.01% 4258
2019
Q3 		$114K Buy
21,800
+500
+2% +$2.49K ﹤0.01% 3815
2019
Q2 		$131K Buy
21,300
+4,500
+27% +$21.7K ﹤0.01% 3915
2019
Q1 		$78K Sell
16,800
-46,300
-73% -$209K ﹤0.01% 4224
2018
Q4 		$256K Sell
63,100
-16,300
-21% -$83K ﹤0.01% 3384
2018
Q3 		$498K Buy
79,400
+11,200
+16% +$86K ﹤0.01% 3116
2018
Q2 		$509K Hold
68,200
– – ﹤0.01% 3082
2018
Q1 		$509K Sell
68,200
-3,800
-5% -$25.3K ﹤0.01% 3082
2017
Q4 		$428K Sell
72,000
-300
-0.4% -$1.82K ﹤0.01% 3192
2017
Q3 		$532K Buy
72,300
+24,000
+50% +$152K ﹤0.01% 2542
2017
Q2 		$336K Sell
48,300
-18,300
-27% -$135K ﹤0.01% 2878
2017
Q1 		$639K Buy
66,600
+11,900
+22% +$119K ﹤0.01% 2129
2016
Q4 		$473K Buy
54,700
+25,500
+87% +$188K ﹤0.01% 2695
2016
Q3 		$167K Buy
+29,200
New +$177K ﹤0.01% 3940

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wolverine Trading's PGNX Position: Q1 2020 in Review

Wolverine Trading sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 18,938 shares — an estimated $96K sold.

Wolverine Trading first reported a position in PGNX in Q3 2016 and held it in 9 quarters. The position peaked at $152K in Q2 2017. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • Wolverine Trading reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • Wolverine Trading sold 18,938 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $96K.
  • Wolverine Trading first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 9 quarters.
  • Wolverine Trading's Progenics Pharmaceuticals Inc position peaked at $152K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Wolverine Trading's 13F filing for Q1 2020, filed 11 May 2020.